John W. Ostrominski

1.8k total citations · 2 hit papers
58 papers, 524 citations indexed

About

John W. Ostrominski is a scholar working on Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism and Pulmonary and Respiratory Medicine. According to data from OpenAlex, John W. Ostrominski has authored 58 papers receiving a total of 524 indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Cardiology and Cardiovascular Medicine, 26 papers in Endocrinology, Diabetes and Metabolism and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in John W. Ostrominski's work include Heart Failure Treatment and Management (25 papers), Cardiovascular Function and Risk Factors (20 papers) and Diabetes Treatment and Management (19 papers). John W. Ostrominski is often cited by papers focused on Heart Failure Treatment and Management (25 papers), Cardiovascular Function and Risk Factors (20 papers) and Diabetes Treatment and Management (19 papers). John W. Ostrominski collaborates with scholars based in United States, United Kingdom and Singapore. John W. Ostrominski's co-authors include Muthiah Vaduganathan, Rahul Aggarwal, Mikhail Kosiborod, Javed Butler, Gregg C. Fonarow, Eric B. Collins, Christina M. Parrinello, Thomas M. O’Connell, Jamie S. Hirsch and Suzanne V. Arnold and has published in prestigious journals such as The Lancet, JAMA and Circulation.

In The Last Decade

John W. Ostrominski

39 papers receiving 520 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prevalence of Cardiovascular-Kidney-Metabolic Syndrome Stages in US Adults, 2011-2020

2024 157 citations Rahul Aggarwal, John W. Ostrominski et al. JAMA profile →
Prevalence and Overlap of Cardiac, Renal, and Metabolic Conditions in US Adults, 1999-2020

2023 107 citations John W. Ostrominski, Jamie S. Hirsch et al. profile →

Peers

John W. Ostrominski

CCM

EDM

EPIDE

NEPHR

Elisa T. Lee United States

Katsuhito Kato Japan

J. Rafael Jiménez-Flores Mexico

Chi Wang China

Xiangbin Zhong China

Farid Kurniawan Indonesia

Lisanne Tap Netherlands

Ioannis Andrikou Greece

Kazuya Fujihara Japan

Tiến Hoàng Anh Vietnam

Elisa T. Lee United States

John W. Ostrominski

253 ×1.1

CCM

111 ×0.6

EDM

81 ×0.9

EPIDE

43 ×0.7

48 ×0.8

NEPHR

Citations per year, relative to John W. Ostrominski John W. Ostrominski (= 1×) peers Elisa T. Lee

Countries citing papers authored by John W. Ostrominski

Since Specialization

Citations

This map shows the geographic impact of John W. Ostrominski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John W. Ostrominski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John W. Ostrominski more than expected).

Fields of papers citing papers by John W. Ostrominski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John W. Ostrominski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John W. Ostrominski. The network helps show where John W. Ostrominski may publish in the future.

Co-authorship network of co-authors of John W. Ostrominski

This figure shows the co-authorship network connecting the top 25 collaborators of John W. Ostrominski. A scholar is included among the top collaborators of John W. Ostrominski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John W. Ostrominski. John W. Ostrominski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pabón, Maria, John W. Ostrominski, Brian Claggett, et al.. (2025). PROGNOSTIC IMPACT OF HEPATORENAL DYSFUNCTION AND CARDIOVASCULAR-KIDNEYMETABOLIC MULTIMORBIDITY IN HEART FAILURE: A PARTICIPANT-LEVEL POOLED ANALYSIS OF THE PARADIGM-HF AND PARAGON-HF TRIALS. Journal of the American College of Cardiology. 85(12). 1339–1339.

Lassen, Mats Christian Højbjerg, John W. Ostrominski, Brian Claggett, et al.. (2025). Obesity and Risk of Kidney Outcomes in Heart Failure With Preserved Ejection Fraction. JACC Heart Failure. 13(8). 102498–102498. 2 indexed citations

Ostrominski, John W., Muthiah Vaduganathan, Brian Claggett, et al.. (2025). Finerenone and NYHA Functional Class in Heart Failure. JACC Heart Failure. 14(1). 102440–102440.

Lassen, Mats Christian Højbjerg, John W. Ostrominski, Brian Claggett, et al.. (2025). ALDOSTERONE DYSREGULATION AND RISK OF CARDIOVASCULAR OUTCOMES:THE ATHEROSCLEROSIS RISK IN COMMUNITIES STUDY. Journal of the American College of Cardiology. 85(12). 665–665.

Ostrominski, John W., Finnian R. Mc Causland, Brian Claggett, et al.. (2025). Finerenone Across the Spectrum of Kidney Risk in Heart Failure. JACC Heart Failure. 14(1). 102439–102439. 3 indexed citations

Parekh, Tarang, et al.. (2025). State-Level Prevalence of Cardiovascular-Kidney-Metabolic Syndrome Stages in the United States, 2011 to 2023. JACC Advances. 4(6). 101754–101754. 1 indexed citations

Ostrominski, John W., Anindit Chhibber, Effie Kuti, Brendan Clark, & B.M.K. Donato. (2025). Obesity Medication Treatment Perspectives Among People with Overweight or Obesity. Patient Preference and Adherence. Volume 19. 2887–2899.

Ostrominski, John W., Brian Claggett, Chiadi E. Ndumele, et al.. (2025). CARDIOVASCULAR-KIDNEY-METABOLIC SYNDROME STAGES, ECHOCARDIOGRAPHIC CHARACTERISTICS, AND HEART FAILURE RISK: THE ATHEROSCLEROSIS RISK IN COMMUNITIES STUDY. Journal of the American College of Cardiology. 85(12). 1539–1539.

Neuen, Brendon L., John W. Ostrominski, Brian Claggett, et al.. (2024). Bidirectional Relationship Between Kidney Disease Progression and Cardiovascular Events in Type 2 Diabetes. Journal of the American College of Cardiology. 84(22). 2246–2250. 5 indexed citations

10.

Ostrominski, John W., Rahul Aggarwal, Brian Claggett, et al.. (2024). Generalizability of the Spectrum of Kidney Risk in the FINEARTS-HF Trial to U.S. Adults With Heart Failure. Journal of Cardiac Failure. 30(9). 1170–1174. 4 indexed citations

11.

Ostrominski, John W., Ersilia M. DeFilippis, Kannu Bansal, et al.. (2024). Contemporary American and European Guidelines for Heart Failure Management. JACC Heart Failure. 12(5). 810–825. 23 indexed citations

12.

Ostrominski, John W., et al.. (2024). Abstract P393: Trends in Risk Factor Control Among US Adults With Cardio-Kidney-Metabolic Multimorbidity, 1999-2020. Circulation. 149(Suppl_1).

13.

Lassen, Mats Christian Højbjerg, Kristoffer Grundtvig Skaarup, Muthiah Vaduganathan, et al.. (2024). Forecasting cardiovascular risk reduction with semaglutide in overweight and obese with heart disease: a nationwide cohort study. European Journal of Preventive Cardiology. 32(3). 259–261.

14.

Ostrominski, John W., Mats Christian Højbjerg Lassen, Brian Claggett, et al.. (2024). Sodium-glucose co-transporter 2 inhibitors and new-onset diabetes in cardiovascular or kidney disease. European Heart Journal. 46(14). 1321–1331. 3 indexed citations

15.

Aggarwal, Rahul, John W. Ostrominski, & Muthiah Vaduganathan. (2024). Prevalence of Cardiovascular-Kidney-Metabolic Syndrome Stages in US Adults, 2011-2020. JAMA. 331(21). 1858–1858. 157 indexed citations breakdown →

16.

Ostrominski, John W., Scott D. Solomon, & Muthiah Vaduganathan. (2024). Heart failure with preserved ejection fraction therapy: combining sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists. European Heart Journal. 45(30). 2748–2751. 4 indexed citations

17.

Neuen, Brendon L., John W. Ostrominski, Brian Claggett, et al.. (2024). Bidirectional relationship between kidney disease progression and cardiovascular events in type 2 diabetes: new Insights from the CANVAS Program and CREDENCE trial. European Heart Journal. 45(Supplement_1).

18.

Lassen, Mats Christian Højbjerg, John W. Ostrominski, Brian Claggett, et al.. (2024). Cardiovascular-Kidney-Metabolic Overlap in Heart Failure with Preserved Ejection Fraction: Cardiac Structure and Function, Clinical Outcomes, and Response to Sacubitril/Valsartan in PARAGON-HF. European Journal of Heart Failure. 26(8). 1762–1774. 10 indexed citations

19.

Ostrominski, John W. & Muthiah Vaduganathan. (2023). Chapter 2: Clinical and Mechanistic Potential of Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors in Heart Failure with Preserved Ejection Fraction. The American Journal of Medicine. 137(2). S9–S24. 7 indexed citations

20.

Ostrominski, John W., Muthiah Vaduganathan, Senthil Selvaraj, et al.. (2023). Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial. Circulation. 148(24). 1945–1957. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact